List view / Grid view
In this article, Dr Mary Spellman, Chief Medical Officer and Senior Vice President of R&D at Castle Creek Biosciences, discusses how a versatile dual platform of ex vivo and in vivo gene therapy technologies is being utilised for the development of novel gene therapies for a broad range of rare…
Study in mice significantly slowed liver tumour growth and activated anti-tumour immune response, highlighting an effective immunotherapy for liver cancer.
Researchers have developed a novel method for enhancing CAR T therapy through a drug combination and cellular engineering that improves the strength and durability of the tumour-killing effect of a CAR T directed against AML.
Scientists have gained new insights into the way G protein-coupled receptors operate, a step toward the development of improved drugs with fewer side effects.
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
Scientists have created a tiny, bioengineered 3D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, a pair of rare, devastating neuromuscular diseases.
Pfizer has announced its acquisition of ReViral to advance disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus infections and prevent illness through vaccination.
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
An experimental drug for liver cancer and Dasatinib, approved for chronic myeloid leukaemia could be repurposed to treat Alzheimer's disease.
Fluoxetine - best known as Prozac - protected the macula from inflammation and degeneration in mice and could become a future treatment.
One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
